Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) EBIT: 2014-2024

Historic EBIT for Spyre Therapeutics (SYRE) over the last 11 years, with Dec 2024 value amounting to -$208.6 million.

  • Spyre Therapeutics' EBIT fell 2.70% to -$56.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$213.6 million, marking a year-over-year decrease of 10.57%. This contributed to the annual value of -$208.6 million for FY2024, which is 13.92% up from last year.
  • As of FY2024, Spyre Therapeutics' EBIT stood at -$208.6 million, which was up 13.92% from -$242.3 million recorded in FY2023.
  • Spyre Therapeutics' EBIT's 5-year high stood at -$65.6 million during FY2021, with a 5-year trough of -$242.3 million in FY2023.
  • Its 3-year average for EBIT is -$178.6 million, with a median of -$208.6 million in 2024.
  • As far as peak fluctuations go, Spyre Therapeutics' EBIT rose by 19.43% in 2021, and later crashed by 185.80% in 2023.
  • Spyre Therapeutics' EBIT (Yearly) stood at -$81.5 million in 2020, then climbed by 19.43% to -$65.6 million in 2021, then dropped by 29.14% to -$84.8 million in 2022, then plummeted by 185.80% to -$242.3 million in 2023, then grew by 13.92% to -$208.6 million in 2024.